Taking inventory of the Packers' offseason needs, Schneidman suggested Green Bay should shop in the cornerback free-agent market, which includes Vikings Pro Bowl corner Byron Murphy Jr. at the top ...

Featured here, the Income Statement (earnings report) for 10X Genomics Inc, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income ...

The biggest stories of the day delivered to your inbox.

The Realme P3 Pro is available in three variants in India. These include 8GB+128GB for Rs 23,999, 8GB+256GB for Rs 24,999, and 12GB+256GB for Rs 26,999. It comes in three shades: Nebula Glow ...

The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08 ... or reduced their stakes in TXG. RA Capital Management L.P. purchased a new position ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

PLEASANTON, Calif. - In a significant development in the biotechnology patent landscape, 10x Genomics Inc. (NASDAQ:TXG), currently valued at $1.2 billion, has successfully obtained a worldwide ...

Featured here, the Cash Flow Statement for 10X Genomics Inc, showing the changes in the company's cash and cash equivalents, broken down to operating, investing and financing activities over each of ...

Founded in 2012, 10x Genomics (NASDAQ:TXG) develops single-cell and spatial genomics solutions, enabling researchers to analyze biological systems at high resolution. Push for growth has led to ...

Commissions do not affect our editors' opinions or evaluations. The price-to-earnings ratio, or P/E ratio, helps you compare the price of a company’s stock to the earnings the company generates.

TSE:TXG opened at C$31.59 on Friday. The stock has a market cap of C$1.92 billion, a PE ratio of 16.98, a P/E/G ratio of 0.02 and a beta of 1.34. The business’s 50-day simple moving average is C ...

The chart above depicts the trend in analyst earnings per share (EPS) forecasts for 10X Genomics Inc for the upcoming quarter. Analysts have reduced this quarter's expectations by -81.2% for EPS from ...